Global Bacteriophage Therapy Market report offers Market Size, Dynamics, Regional Market Share, Top Key Players, Latest trends, Growth factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024
Market Outline: Global Bacteriophage Therapy Market
Bacteriophage therapy or phage therapy is used to treat the pathogenic bacterial infections with viruses. These are more specific than bacteria and do not cause any harm to host organism as well as beneficial bacteria such as gut flora. Bacteriophages are most abundant in biosphere and isolated, concentrated, and applied in specific area to eradicate the bacteria. They cause the bacterium to lyse by disrupting the bacterial metabolism. The major advantages with bacteriophages over the antibiotics include very specific, replicate at the site of infection, less side effects and rapidly select the new phages. Bacteriophages can be administered by oral, rectal, intravenous, intrapleural injections, and local applications.
Free sample of this report is available upon request @
Increase in the incidence of antibiotic resistant bacteria strengthen the use of bacteriophage therapy. Moreover, FDA approval for bacteriophage therapies, stringent regulations for the use of antibiotics, promising pipeline drugs under various stages of clinical trials, rise in funding from the public and private sector for bacteriophage therapy research, and wide range of applications with bacteriophage therapeutics are propel the market over the forecast years.
Moreover, most of the market players and research institutes are focused on the R&D activities to develop newer bacteriophage therapies to treat the chronic infections. For instance,
Free TOC of this report is available upon request @
- AmpliPHI Biosciences Corporation develops the bacteriophage therapeutics AB-SA01 and AB-PA01. AB-SA01 is developed for the treatment of multiple drug resistant aureus infections and completed the two Phase 1 studies. AB-PA01 developed for the treatment of aeruginosa infections and completed the pre-clinical studies
- Technophage has received FDA clearance for its Investigational New Drug (IND) application for the initiation of human clinical trials for bacteriophage TP-102 in the treatment of chronic ulcers such as diabetic foot disease
Ask Analyst for Full Information about this report @
- In January 2018, Pherecydes Pharma raised $ 10.3 Mn Series B funding for the treatment of Staphylococcus aureus infection and PNEUMOPHAGE for the treatment of Pseudomonas aeruginosa respiratory tract by GO CAPITAL, ACE Management, and Auriga Partners infections.
- In March 2017, Intralytix, Inc. received GRAS recognition from FDA for ShigaShield, a non-chemical antimicrobial preparation to control waterborne / foodborne bacterial pathogen. Shigella including three major disease-causing species S, sonnei , S. flexneri , and S. Moreover, company collaborates with Ferring Pharmaceuticals on bacteriophage-based inflammatory bowel disease (IBD) drug development project
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/bacteriophage-therapy-market/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firms, which follows a holistic approach to solve the needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and making better decisions. We provide consulting, syndicated and customized market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Contact Person: Rajesh Babu
Role: Marketing Lead
Email: sales@precisionbusinessinsights.com